-+ 0.00%
-+ 0.00%
-+ 0.00%

Gilead to Present Phase 3 Livdelzi Data in Primary Biliary Cholangitis at Liver Meeting 2026

PUBT·10/22/2026 12:08:05
Listen to the news
Gilead to Present Phase 3 Livdelzi Data in Primary Biliary Cholangitis at Liver Meeting 2026
  • Gilead Sciences will present new Livdelzi and Hepcludex data at The Liver Meeting, November 5-9, 2026, in Denver.
  • Phase 3 IDEAL results will examine Livdelzi’s effect on a liver disease marker in adults with primary biliary cholangitis.
  • Long-term Livdelzi analyses report sustained efficacy and safety through five years; separate findings show clinically meaningful fatigue improvement.
  • Hepcludex research will assess sustained treatment response in chronic hepatitis delta; another analysis suggests improvement in liver-related hypertension for some patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610220800BIZWIRE_USPR_____20261021_BW867668) on October 22, 2026, and is solely responsible for the information contained therein.